Castle Biosciences is pushing into new skin and gut tests, but insurers may be slow to pay for them and could tighten access as drug costs come under the spotlight. If coverage setbacks or rising lab costs hit at the wrong time, the company’s long-term growth story could look very different from what many expect.Read more
Castle Biosciences is pushing beyond its core cancer testing into new areas, betting that better proof for doctors and wider insurance coverage will drive much broader use. But coverage decisions and fast-moving competition could squeeze pricing and make that growth harder than it looks.Read more
Catalysts About Castle Biosciences Castle Biosciences develops and commercializes gene expression profile tests that help physicians personalize treatment decisions in dermatology and gastroenterology. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
